Figure 3From: Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade In patients with moderate/poorly differentiated tumor, those with low Annexin A1 expression benefited from TPF induction chemotherapy on overall survival (A) and distant metastasis-free survival (D), but not benefit from TPF induction chemotherapy on disease-free survival (B) or locoregional recurrence-free survival (C). Back to article page